DOCSLIB.ORG

Phosphodiesterases As Therapeutic Targets for Respiratory Diseases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

University of Groningen Phosphodiesterases as therapeutic targets for respiratory diseases Zuo, Haoxiao; Cattani-Cavalieri, Isabella; Musheshe, Nshunge; Nikolaev, Viacheslav O; Schmidt, Martina Published in: Pharmacology & Therapeutics DOI: 10.1016/j.pharmthera.2019.02.002 IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2019 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Zuo, H., Cattani-Cavalieri, I., Musheshe, N., Nikolaev, V. O., & Schmidt, M. (2019). Phosphodiesterases as therapeutic targets for respiratory diseases. Pharmacology & Therapeutics, 197, 225-242. https://doi.org/10.1016/j.pharmthera.2019.02.002 Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 27-09-2021 Pharmacology & Therapeutics 197 (2019) 225–242 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Phosphodiesterases as therapeutic targets for respiratory diseases Haoxiao Zuo a,c,⁎, Isabella Cattani-Cavalieri a,b,d,NshungeMusheshea, Viacheslav O. Nikolaev c,e, Martina Schmidt a,b a Department of Molecular Pharmacology, University of Groningen, the Netherlands b Groningen Research Institute for Asthma and COPD, GRIAC, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands c Institute of Experimental Cardiovascular Research, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany d Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil e German Center for Cardiovascular Research (DZHK), 20246 Hamburg, Germany article info abstract Chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma, affect millions Keywords: of people all over the world. Cyclic adenosine monophosphate (cAMP) which is one of the most important second phosphodiesterases messengers, plays a vital role in relaxing airway smooth muscles and suppressing inflammation. Given its vast cAMP cGMP role in regulating intracellular responses, cAMP provides an attractive pharmaceutical target in the treatment COPD of chronic respiratory diseases. Phosphodiesterases (PDEs) are enzymes that hydrolyze cyclic nucleotides and asthma help control cyclic nucleotide signals in a compartmentalized manner. Currently, the selective PDE4 inhibitor, roflumilast, is used as an add-on treatment for patients with severe COPD associated with bronchitis and a history of frequent exacerbations. In addition, other novel PDE inhibitors are in different phases of clinical trials. The current review provides an overview of the regulation of various PDEs and the potential application of selective PDE inhibitors in the treatment of COPD and asthma. The possibility to combine various PDE inhibitors as a way to increase their therapeutic effectiveness is also emphasized. © 2019 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Contents 1. Introduction............................................... 226 2. SystematicoverviewofthePDEsuperfamily................................ 226 3. PDE3.................................................. 227 4. PDE4.................................................. 228 5. PDE5.................................................. 231 6. PDE7.................................................. 232 7. PDE8.................................................. 232 8. DualPDEinhibitors........................................... 233 9. Futuredirections............................................. 234 Authorcontributions............................................. 235 Conflictsofinterest.............................................. 235 Acknowledgments.............................................. 236 References.................................................. 236 Abbreviations: COPD, chronic obstructive pulmonary disease; β2-AR, β2-adrenoceptor; PDE, phosphodiesterase; cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; ASM, airway smooth muscle; ACs, adenylyl cyclases; PKA, cAMP-dependent protein kinase; PKG, cGMP-dependent protein kinase; Epacs, exchange proteins directly ac- tivated by cAMP; UCRs, upstream conserved regions; CS, cigarette smoke; PCLS, precision cut lung slices; MMP, matrix metalloproteinase; GM-CSF, granulocyte/macrophage colony- stimulating factor; CCL, C-C motif ligand; CXCL, C-X-C motif ligand; TNF-α, tumor necrosis factor-α; LPS, lipopolysaccharides; TNF-α, tumor necrosis factor-α; IL, interleukin; IFN-γ,in- terferon gamma; BAL, bronchoalveolar lavage; NF-κB, nuclear factor kappa B; EMT, epithelial-to-mesenchymal transition; TGF-β1, transforming growth factor beta1; HDM, house dust mite; WT, wild type; NO, nitric oxide; PAH, polycyclic aromatic hydrocarbons; EP, E prostanoid receptors.. ⁎ Corresponding author at: Antonius Deusinglaan 1, Groningen, the Netherlands. E-mail address: [email protected] (H. Zuo). https://doi.org/10.1016/j.pharmthera.2019.02.002 0163-7258/© 2019 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 226 H. Zuo et al. / Pharmacology & Therapeutics 197 (2019) 225–242 1. Introduction asthma treatment. The possibility to combine various PDE inhibitors to increase their therapeutic effectiveness is also emphasized. Respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma are among the leading causes of morbidity and 2. Systematic overview of the PDE superfamily mortality today. COPD and asthma combined affect at least 300 million people worldwide, making investigation of more therapeutic targets Cyclic adenosine monophosphate (cAMP) and cyclic guanosine and the development of effective drugs a relevant task in the treatment monophosphate (cGMP) are ubiquitous second messengers. cAMP of these respiratory diseases (Vogelmeier et al., 2017). and cGMP play important roles in regulating numerous cellular func- COPD and asthma are characterized by airway obstruction, chronic tions in physiology and pathology of the lung, including but not limited inflammation, and airway remodeling. Despite both COPD and asthma to the airway smooth muscle (ASM) tone, cell proliferation, differentia- being characterized by airway obstruction, the airway obstruction in tion, apoptosis, migration, secretion of inflammatory mediators, deposi- COPD is progressive and not fully reversible, while that in asthma tion of extracellular matrix, and the maintenance of the endothelial and is reversible by bronchodilators and is associated with airway epithelial barrier (Beavo & Brunton, 2002; Billington, Ojo, Penn, & Ito, hyperresponsiveness (Guerra, 2009; Hogg & Timens, 2009; Meurs, 2013; Sayner, 2011; Zhang, Zhang, Qi, & Xu, 2016). Gosens, & Zaagsma, 2008). In addition, airway inflammation in COPD is Following activation of adenylyl cyclases (ACs) or guanylyl cyclases, characterized by an increased number of neutrophils, macrophages cAMP and cGMP are synthesized from adenosine triphosphate and gua- and CD8+ T-lymphocytes, while that in asthma is characterized by the nosine triphosphate, respectively (Omori & Kotera, 2007). Subse- infiltration of eosinophils, mast cells and CD4+ T-lymphocytes (Mauad quently, cAMP and cGMP bind to specific intracellular effector & Dolhnikoff, 2008; Vogelmeier et al., 2017; Welte & Groneberg, 2006). proteins, such as: cyclic nucleotide-gated ion channels, cAMP- Currently, therapeutic management of COPD relies mainly on the use dependent protein kinase (PKA), cGMP-dependent protein kinase of bronchodilators (β2-adrenoceptor (β2-AR) agonists, anticholinergics (PKG), exchange proteins directly activated by cAMP (Epacs) and theophylline), and a combination therapy of inhaled corticosteroid (Oldenburger, Maarsingh, & Schmidt, 2012; Omori & Kotera, 2007; plus long-acting β2-AR agonists. In patients with severe COPD associated Pfeifer, Kilić, & Hoffmann, 2013) and the most recently described with bronchitis and a history of frequent exacerbations, the phosphodies- Popeye domain containing proteins which bind cAMP with a high affin- terase (PDE) 4 inhibitor roflumilast is typically used as an add-on treat- ity (Schindler & Brand, 2016). The intracellular cyclic nucleotide concen- ment to the above mentioned therapies (Giembycz & Maurice, 2014). In trations are substantially determined by PDEs (shown in Fig. 1), which asthma treatment and/or management, the combination therapies of in- hydrolyze cAMP and cGMP and prevent it from diffusing to other com- haled corticosteroid and short-acting β2-AR agonists or long-acting β2- partments thereby compartmentalizing the cyclic nucleotide signal.
Recommended publications
  • Synthesis of Indole and Oxindole Derivatives Incorporating Pyrrolidino, Pyrrolo Or Imidazolo Moieties

    Synthesis of Indole and Oxindole Derivatives Incorporating Pyrrolidino, Pyrrolo Or Imidazolo Moieties

    From DEPARTMENT OF BIOSCIENCES AT NOVUM Karolinska Institutet, Stockholm, Sweden SYNTHESIS OF INDOLE AND OXINDOLE DERIVATIVES INCORPORATING PYRROLIDINO, PYRROLO OR IMIDAZOLO MOIETIES Stanley Rehn Stockholm 2004 All previously published papers have been reproduced with permission from the publishers. Published and printed by Karolinska University Press Box 200, SE-171 77 Stockholm, Sweden © Stanley Rehn, 2004 ISBN 91-7140-169-5 Till Amanda Abstract The focus of this thesis is on the synthesis of oxindole- and indole-derivatives incorporating pyrrolidins, pyrroles or imidazoles moieties. Pyrrolidino-2-spiro-3’-oxindole derivatives have been prepared in high yielding three-component reactions between isatin, α-amino acid derivatives, and suitable dipolarophiles. Condensation between isatin and an α-amino acid yielded a cyclic intermediate, an oxazolidinone, which decarboxylate to give a 1,3-dipolar species, an azomethine ylide, which have been reacted with several dipolarophiles such as N- benzylmaleimide and methyl acrylate. Both N-substituted and N-unsubstituted α- amino acids have been used as the amine component. 3-Methyleneoxindole acetic acid ethyl ester was reacted with p- toluenesulfonylmethyl isocyanide (TosMIC) under basic conditions which gave (in a high yield) a colourless product. Two possible structures could be deduced from the analytical data, a pyrroloquinolone and an isomeric ß-carboline. To clarify which one of the alternatives that was actually formed from the TosMIC reaction both the ß- carboline and the pyrroloquinolone were synthesised. The ß-carboline was obtained when 3-ethoxycarbonylmethyl-1H-indole-2-carboxylic acid ethyl ester was treated with a tosylimine. An alternative synthesis of the pyrroloquinolone was performed via a reduction of a 2,3,4-trisubstituted pyrrole obtained in turn by treatment of a vinyl sulfone with ethyl isocyanoacetate under basic conditions.
  • Effects of Phosphodiesterase Inhibitors on Human Lung Mast Cell and Basophil Function

    Effects of Phosphodiesterase Inhibitors on Human Lung Mast Cell and Basophil Function

    British Journal of Pharmacology (1997) 121, 287 ± 295 1997 Stockton Press All rights reserved 0007 ± 1188/97 $12.00 Eects of phosphodiesterase inhibitors on human lung mast cell and basophil function Marie C. Weston, Nicola Anderson & 1Peter T. Peachell Department of Medicine & Pharmacology, University of Sheeld, Royal Hallamshire Hospital (Floor L), Glossop Road, Sheeld S10 2JF 1 The non-hydrolysable cyclic AMP analogue, dibutyryl (Bu2)-cyclic AMP, inhibited the stimulated release of histamine from both basophils and human lung mast cells (HLMC) in a dose-dependent manner. The concentrations required to inhibit histamine release by 50% (IC50) were 0.8 and 0.7 mM in basophils and HLMC, respectively. The cyclic GMP analogue, Bu2-cyclic GMP, was ineective as an inhibitor of histamine release in basophils and HLMC. 2 The non-selective phosphodiesterase (PDE) inhibitors, theophylline and isobutyl-methylxanthine (IBMX) inhibited the IgE-mediated release of histamine from both human basophils and HLMC in a dose-dependent fashion. IBMX and theophylline were more potent inhibitors in basophils than HLMC. IC50 values for the inhibition of histamine release were, 0.05 and 0.2 mM for IBMX and theophylline, respectively, in basophils and 0.25 and 1.2 mM for IBMX and theophylline in HLMC. 3 The PDE 4 inhibitor, rolipram, attenuated the release of both histamine and the generation of sulphopeptidoleukotrienes (sLT) from activated basophils at sub-micromolar concentrations but was ineective at inhibiting the release of histamine and the generation of both sLT and prostaglandin D2 (PGD2) in HLMC. Additional PDE 4 inhibitors, denbufylline, Ro 20-1724, RP 73401 and nitraquazone, were all found to be eective inhibitors of mediator release in basophils but were ineective in HLMC unless high concentrations (1 mM) were employed.
  • PDE4-Inhibitors: a Novel, Targeted Therapy for Obstructive Airways Disease Zuzana Diamant, Domenico Spina

    PDE4-Inhibitors: a Novel, Targeted Therapy for Obstructive Airways Disease Zuzana Diamant, Domenico Spina

    PDE4-inhibitors: A novel, targeted therapy for obstructive airways disease Zuzana Diamant, Domenico Spina To cite this version: Zuzana Diamant, Domenico Spina. PDE4-inhibitors: A novel, targeted therapy for obstructive airways disease. Pulmonary Pharmacology & Therapeutics, 2011, 24 (4), pp.353. 10.1016/j.pupt.2010.12.011. hal-00753954 HAL Id: hal-00753954 https://hal.archives-ouvertes.fr/hal-00753954 Submitted on 20 Nov 2012 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Accepted Manuscript Title: PDE4-inhibitors: A novel, targeted therapy for obstructive airways disease Authors: Zuzana Diamant, Domenico Spina PII: S1094-5539(11)00006-X DOI: 10.1016/j.pupt.2010.12.011 Reference: YPUPT 1071 To appear in: Pulmonary Pharmacology & Therapeutics Received Date: 2 October 2010 Revised Date: 5 December 2010 Accepted Date: 24 December 2010 Please cite this article as: Diamant Z, Spina D. PDE4-inhibitors: A novel, targeted therapy for obstructive airways disease, Pulmonary Pharmacology & Therapeutics (2011), doi: 10.1016/j.pupt.2010.12.011 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript.
  • The Single Cyclic Nucleotide-Specific Phosphodiesterase of the Intestinal Parasite Giardia Lamblia Represents a Potential Drug Target

    The Single Cyclic Nucleotide-Specific Phosphodiesterase of the Intestinal Parasite Giardia Lamblia Represents a Potential Drug Target

    RESEARCH ARTICLE The single cyclic nucleotide-specific phosphodiesterase of the intestinal parasite Giardia lamblia represents a potential drug target Stefan Kunz1,2*, Vreni Balmer1, Geert Jan Sterk2, Michael P. Pollastri3, Rob Leurs2, Norbert MuÈ ller1, Andrew Hemphill1, Cornelia Spycher1¤ a1111111111 1 Institute of Parasitology, Vetsuisse Faculty, University of Bern, Bern, Switzerland, 2 Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute of Molecules, Medicines and Systems (AIMMS), Vrije a1111111111 Universiteit Amsterdam, Amsterdam, The Netherlands, 3 Department of Chemistry and Chemical Biology, a1111111111 Northeastern University, Boston, Massachusetts, United States of America a1111111111 a1111111111 ¤ Current address: Euresearch, Head Office Bern, Bern, Switzerland * [email protected] Abstract OPEN ACCESS Citation: Kunz S, Balmer V, Sterk GJ, Pollastri MP, Leurs R, MuÈller N, et al. (2017) The single cyclic Background nucleotide-specific phosphodiesterase of the Giardiasis is an intestinal infection correlated with poverty and poor drinking water quality, intestinal parasite Giardia lamblia represents a potential drug target. PLoS Negl Trop Dis 11(9): and treatment options are limited. According to the Center for Disease Control and Preven- e0005891. https://doi.org/10.1371/journal. tion, Giardia infections afflict nearly 33% of people in developing countries, and 2% of the pntd.0005891 adult population in the developed world. This study describes the single cyclic nucleotide- Editor: Aaron R. Jex, University of Melbourne, specific phosphodiesterase (PDE) of G. lamblia and assesses PDE inhibitors as a new gen- AUSTRALIA eration of anti-giardial drugs. Received: December 5, 2016 Accepted: August 21, 2017 Methods Published: September 15, 2017 An extensive search of the Giardia genome database identified a single gene coding for a class I PDE, GlPDE.
  • Phosphodiesterase Isoforms and Camp Compartments in The

    Phosphodiesterase Isoforms and Camp Compartments in The

    University of Groningen Phosphodiesterase isoforms and cAMP compartments in the development of new therapies for obstructive pulmonary diseases Schmidt, Martina; Cattani-Cavalieri, Isabella; Nuñez, Francisco J; Ostrom, Rennolds S Published in: Current Opinion in Pharmacology DOI: 10.1016/j.coph.2020.05.002 IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2020 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Schmidt, M., Cattani-Cavalieri, I., Nuñez, F. J., & Ostrom, R. S. (2020). Phosphodiesterase isoforms and cAMP compartments in the development of new therapies for obstructive pulmonary diseases. Current Opinion in Pharmacology, 51, 34-42. https://doi.org/10.1016/j.coph.2020.05.002 Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne- amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
  • Signal Transduction Guide

    Signal Transduction Guide

    Signal Transduction Product Guide | 2007 NEW! Selective T-type Ca2+ channel blockers, NNC 55-0396 and Mibefradil ZM 447439 – Novel Aurora Kinase Inhibitor NEW! Antibodies for Cancer Research EGFR-Kinase Selective Inhibitors – BIBX 1382 and BIBU 1361 DRIVING RESEARCH FURTHER Calcium Signaling Agents ...................................2 G Protein Reagents ...........................................12 Cell Cycle and Apoptosis Reagents .....................3 Ion Channel Modulators ...................................13 Cyclic Nucleotide Related Tools ...........................7 Lipid Signaling Agents ......................................17 Cytokine Signaling Agents ..................................9 Nitric Oxide Tools .............................................19 Enzyme Inhibitors/Substrates/Activators ..............9 Protein Kinase Reagents....................................22 Glycobiology Agents .........................................12 Protein Phosphatase Reagents ..........................33 Neurochemicals | Signal Transduction Agents | Peptides | Biochemicals Signal Transduction Product Guide Calcium Signaling Agents ......................................................................................................................2 Calcium Binding Protein Modulators ...................................................................................................2 Calcium ATPase Modulators .................................................................................................................2 Calcium Sensitive Protease
  • Last Decade of Unconventional Methodologies for the Synthesis Of

    Last Decade of Unconventional Methodologies for the Synthesis Of

    Review molecules Last Decade of Unconventional Methodologies for theReview Synthesis of Substituted Benzofurans Last Decade of Unconventional Methodologies for the Lucia Chiummiento *, Rosarita D’Orsi, Maria Funicello and Paolo Lupattelli Synthesis of Substituted Benzofurans Department of Science, Via dell’Ateneo Lucano, 10, 85100 Potenza, Italy; [email protected] (R.D.); [email protected] (M.F.); [email protected] (P.L.) Lucia Chiummiento * , Rosarita D’Orsi, Maria Funicello and Paolo Lupattelli * Correspondence: [email protected] Department of Science, Via dell’Ateneo Lucano, 10, 85100 Potenza, Italy; [email protected] (R.D.); Academic Editor: Gianfranco Favi [email protected] (M.F.); [email protected] (P.L.) Received:* Correspondence: 22 April 2020; [email protected] Accepted: 13 May 2020; Published: 16 May 2020 Abstract:Academic This Editor: review Gianfranco describes Favi the progress of the last decade on the synthesis of substituted Received: 22 April 2020; Accepted: 13 May 2020; Published: 16 May 2020 benzofurans, which are useful scaffolds for the synthesis of numerous natural products and pharmaceuticals.Abstract: This In review particular, describes new the intramolecular progress of the and last decadeintermolecular on the synthesis C–C and/or of substituted C–O bond- formingbenzofurans, processes, which with aretransition-metal useful scaffolds catalysi for thes or synthesis metal-free of numerous are summarized. natural products(1) Introduction. and (2) Ringpharmaceuticals. generation via In particular, intramolecular new intramolecular cyclization. and (2.1) intermolecular C7a–O bond C–C formation: and/or C–O (route bond-forming a). (2.2) O– C2 bondprocesses, formation: with transition-metal (route b).
  • Phosphodiesterase (PDE)

    Phosphodiesterase (PDE)

    Phosphodiesterase (PDE) Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules. www.MedChemExpress.com 1 Phosphodiesterase (PDE) Inhibitors, Activators & Modulators (+)-Medioresinol Di-O-β-D-glucopyranoside (R)-(-)-Rolipram Cat. No.: HY-N8209 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A (+)-Medioresinol Di-O-β-D-glucopyranoside is a (R)-(-)-Rolipram is the R-enantiomer of Rolipram. lignan glucoside with strong inhibitory activity Rolipram is a selective inhibitor of of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM phosphodiesterase. and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg (R)-DNMDP (S)-(+)-Rolipram Cat. No.: HY-122751 ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (R)-DNMDP is a potent and selective cancer cell (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, AMP(cAMP)-specific phosphodiesterase (PDE) binds PDE3A directly.
  • Anagrelide for Gastrointestinal Stromal Tumor

    Anagrelide for Gastrointestinal Stromal Tumor

    Author Manuscript Published OnlineFirst on December 7, 2018; DOI: 10.1158/1078-0432.CCR-18-0815 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Anagrelide for gastrointestinal stromal tumor Olli-Pekka Pulkka1, Yemarshet K. Gebreyohannes2, Agnieszka Wozniak2, John-Patrick Mpindi3, Olli Tynninen4, Katherine Icay5, Alejandra Cervera5, Salla Keskitalo6, Astrid Murumägi3, Evgeny Kulesskiy3, Maria Laaksonen7, Krister Wennerberg3, Markku Varjosalo6, Pirjo Laakkonen8, Rainer Lehtonen5, Sampsa Hautaniemi5, Olli Kallioniemi3, Patrick Schöffski2, Harri Sihto1*, and Heikki Joensuu1,9* 1Laboratory of Molecular Oncology, Research Programs Unit, Translational Cancer Biology, Department of Oncology, University of Helsinki, Helsinki, Finland. 2Laboratory of Experimental Oncology, Department of Oncology, KU Leuven and Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium. 3Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland 4Department of Pathology, Haartman Institute, University of Helsinki and HUSLAB, Helsinki, Finland. 5Research Programs Unit, Genome-Scale Biology, Medicum and Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland. 6Institute of Biotechnology, University of Helsinki, Helsinki, Finland. 7MediSapiens Ltd., Helsinki, Finland 8Research Programs Unit, Translational Cancer Biology, University of Helsinki, Helsinki, Finland. 9Comprehensive Cancer Center,
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule

    Pharmaceutical Appendix to the Harmonized Tariff Schedule

    Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • Rolipram, but Not Siguazodan Or Zaprinast, Inhibits the Excitatory Noncholinergic Neurotransmission in Guinea-Pig Bronchi

    Rolipram, but Not Siguazodan Or Zaprinast, Inhibits the Excitatory Noncholinergic Neurotransmission in Guinea-Pig Bronchi

    Eur Respir J, 1994, 7, 306–310 Copyright ERS Journals Ltd 1994 DOI: 10.1183/09031936.94.07020306 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 Rolipram, but not siguazodan or zaprinast, inhibits the excitatory noncholinergic neurotransmission in guinea-pig bronchi Y. Qian, V. Girard, C.A.E. Martin, M. Molimard, C. Advenier Rolipram, but not siguazodan or zaprinast, inhibits the excitatory noncholinergic neuro- Faculté de Médecine Paris-Ouest Labora- transmission in guinea-pig bronchi. Y. Qian, V. Girard C.A.E. Martin, M. Molimard, toire de Pharmacologie, Paris, France. C. Advenier. ERS Journals Ltd 1994. ABSTRACT: Theophylline has been reported to inhibit excitatory noncholinergic Correspondence: C. Advenier Faculté de Médecine Paris-Ouest but not cholinergic-neurotransmission in guinea-pig bronchi. As theophylline might Laboratoire de Pharmacologie exert this effect through an inhibition of phosphodiesterases (PDE), and since many 15, Rue de l'Ecole de Médecine types of PDE have now been described, the aim of this study was to investigate the F-75270 Paris Cedex 06 effects of three specific inhibitors of PDE on the electrical field stimulation (EFS) France of the guinea-pig isolated main bronchus in vitro. The drugs used were siguazo- dan, rolipram and zaprinast, which specifically inhibit PDE types, III, IV and V, Keywords: C-fibres respectively. neuropeptides Guinea-pig bronchi were stimulated transmurally with biphasic pulses (16 Hz, 1 phosphodiesterase inhibitors ms, 320 mA for 10 s) in the presence of indomethacin 10-6 M and propranolol 10-6 Received: March 11 1993 M. Two successive contractile responses were observed: a rapid cholinergic con- Accepted after revision August 8 1993 traction, followed by a long-lasting contraction due to a local release of neuropep- tides from C-fibre endings.
  • Xagrid, INN-Anagrelide

    Xagrid, INN-Anagrelide

    SCIENTIFIC DISCUSSION 1. Introduction Anagrelide hydrochloride monohydrate is a novel imidazoquinazoline originally developed as an inhibitor of platelet aggregation but subsequently found to have value as a platelet-lowering agent for the treatment of patients suffering from Essential thrombocythaemia (ET). ET is one of a number of chronic myeloproliferative disorders characterised by an elevated platelet count due to an autonomous clonal proliferation of bone marrow megakaryocytes. The underlying cause of this proliferation is unknown. Platelet function is generally normal and the cells are able to undergo aggregation and to participate in the haemostatic process in a more or less normal manner. The diagnosis is one of exclusion of reactive causes and other myeloproliferative disorders (MPDs) according to internationally agreed criteria of the Polycythaemia Vera Study Group (PVSG). The main criterion is a sustained platelet level of >600 x 109/L for more than two months. It is estimated that the prevalence of ET in the European Union (EU) is 2-3 per 10,000 persons. ET is a condition that may affect anyone at any stage of life from childhood although the median age of presentation is 60 years. Literature and clinical experience indicate a preponderance of female patients between the ages of 25 and 50 years. Up to two thirds of patients with ET are asymptomatic and a significant number of patients are now being diagnosed as an incidental consequence of the analysis of full blood counts for other health reasons. Generally, the older patient is more likely to be symptomatic at presentation, although younger patients may present with major complications.